At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
Dupilumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Dupilumab, Placebo, and 1 other intervention for Atopic Dermatitis (AD). Completed, enrolled 54 participants across 4 sites in 2 countries.
Detailed Summary
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis (AD)
CountriesCanada, United States
CollaboratorsSanofi
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartDec 2013
Primary CompletionDec 2014
Study CompletionJan 2015
TodayJul 2026
First PostedNov 8, 2013
Enrollment StartDec 31, 2013
Primary CompletionDec 31, 2014
Study CompletionJan 31, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.7 years ago
Interventions
Dupilumabdrug
Placebodrug
Matching placebo
Background treatmentother
Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).